Opendata, web and dolomites

STTDAA

Synthesis of Truncated Tirandamycin A-D Derivatives as new Antihelminthic Agents

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "STTDAA" data sheet

The following table provides information about the project.

Coordinator
GOETEBORGS UNIVERSITET 

Organization address
address: VASAPARKEN
city: GOETEBORG
postcode: 405 30
website: www.gu.se

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Project website http://cmb.gu.se/om_institutionen/personal
 Total cost 173˙857 €
 EC max contribution 173˙857 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2014
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2015
 Duration (year-month-day) from 2015-06-01   to  2017-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GOETEBORGS UNIVERSITET SE (GOETEBORG) coordinator 173˙857.00

Map

 Project objective

This project entitled “Synthesis of Truncated tirandamycin A-D derivatives as new Antihelminthic Agents (STTDAA)” aims at developing novel asparaginyl tRNA synthetase (AsnRS) inhibitors as potential antihelminthic agents, with new mechanisms of action for potential treatment of lymphatic filariasis (LF). LF is one of the World Health Organization’s (WHO) top 10 neglected tropical diseases (NTDs), This incapacitating disease has infected over 200 million people in 73 tropical and subtropical countries, while more than 1.4 billion people remain at the risk of infection. Thus a top priority of the WHO is to search for new antihelminthic drugs that kill adult worms (macrofilaricides), have new mechanisms of action, and exhibit fewer side effects than currently available medications such as albendazole and ivermectin to which parasite resistance has already been confirmed. To this end, two distinctively different but complimentary synthetic approaches towards tirandamycin A-D (TAMs A-D) derivatives, as AsnRS inhibitors will be developed. This will be followed by intensive structure activity relationship (SAR) studies, which will further promote improvements of the bioactivity and the drug characteristic of the synthesized derivatives. These studies will compose a vital part of a more comprehensive drug development program.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "STTDAA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "STTDAA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

EPIC (2019)

Evolution of Planktonic Gastropod Calcification

Read More  

iRhomADAM (2020)

Uncovering the role of the iRhom2-ADAM17 interaction in inflammatory signalling

Read More  

NaWaTL (2020)

Narrative, Writing, and the Teotihuacan Language: Exploring Language History Through Phylogenetics, Epigraphy and Iconography

Read More